1. Home
  2. SLN vs OPRT Comparison

SLN vs OPRT Comparison

Compare SLN & OPRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$6.91

Market Cap

236.2M

Sector

Health Care

ML Signal

HOLD

Logo Oportun Financial Corporation

OPRT

Oportun Financial Corporation

HOLD

Current Price

$4.29

Market Cap

249.3M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLN
OPRT
Founded
1994
2005
Country
United Kingdom
United States
Employees
116
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
236.2M
249.3M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
SLN
OPRT
Price
$6.91
$4.29
Analyst Decision
Buy
Buy
Analyst Count
5
2
Target Price
$42.60
$7.25
AVG Volume (30 Days)
206.4K
647.5K
Earning Date
01-01-0001
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
127.18
EPS
N/A
0.53
Revenue
N/A
$956,685,000.00
Revenue This Year
N/A
$32.79
Revenue Next Year
N/A
$5.51
P/E Ratio
N/A
$8.64
Revenue Growth
N/A
N/A
52 Week Low
$1.97
$4.06
52 Week High
$7.83
$7.73

Technical Indicators

Market Signals
Indicator
SLN
OPRT
Relative Strength Index (RSI) 71.02 30.96
Support Level $5.79 N/A
Resistance Level $7.40 $5.68
Average True Range (ATR) 0.63 0.32
MACD 0.18 -0.10
Stochastic Oscillator 68.64 0.00

Price Performance

Historical Comparison
SLN
OPRT

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About OPRT Oportun Financial Corporation

Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.

Share on Social Networks: